Impact of Levetiracetam on Hypothalamic-Pituitary-Adrenal Axis Dysregulation, Anxiety-, and Depressive-Like Behaviors in Doxorubicin-Treated Mice

Öz

Doxorubicin (DOX) is a highly effective chemotherapeutic agent, yet its clinical utility is frequently compromised by severe neurotoxicity, manifesting as anxiety and depressive-like behaviors. This study investigated the neuroprotective efficacy of the antiepileptic drug levetiracetam (LEV) against DOX-induced affective disorders and explored the underlying neuroinflammatory, oxidative, and neuroendocrine mechanisms. Male BALB/c mice were randomly assigned to Control, DOX, DOX+LEV, and LEV groups. A single intraperitoneal injection of DOX (25 mg/kg) was utilized to induce neurotoxicity, while LEV (100 mg/kg/day) was administered over five consecutive days. Affective behaviors were evaluated using the open field (OF) and forced swim tests (FST). Hippocampal tumor necrosis factor-alpha (TNF-α) and glutathione (GSH) concentrations, alongside serum adrenocorticotropic hormone (ACTH) and cortisol levels, were quantified biochemically. DOX exposure precipitated severe anxiogenic and depressive-like phenotypes, evidenced by significantly reduced center exploration in the OF and increased immobility in the FST, independent of locomotor impairment. These behavioral deficits were mechanically coupled with marked hippocampal GSH depletion, elevated central TNF-α, and systemic hypothalamic-pituitary-adrenal (HPA) axis hyperactivation. Crucially, LEV co-administration completely abrogated the DOX-induced behavioral dysfunctions. This psychotropic efficacy was directly mirrored by the restoration of hippocampal oxidative-inflammatory homeostasis and the strict normalization of systemic ACTH and cortisol levels. DOX triggers affective disturbances driven by a pathological triad of neuroinflammation, oxidative stress, and neuroendocrine dysregulation. LEV effectively counteracts these cascades, highlighting its strong translational potential as an adjunctive therapy to mitigate chemotherapy-induced neuropsychiatric complications.

Anahtar Kelimeler

• Affective disorders
• Hippocampus
• Hypothalamic-pituitary-adrenal axis
• Neuroinflammation
• Oxidative stress

Doksorubisin Uygulanan Farelerde Levetirasetamın HPA Ekseni Disregülasyonu, Anksiyete ve Depresyon Benzeri Davranışlar Üzerindeki Etkisi

Öz

Doksorubisin (DOX) oldukça etkili bir kemoterapötik ajandır; ancak klinik faydası, anksiyete ve depresyon benzeri davranışlar şeklinde tezahür eden şiddetli nörotoksisite nedeniyle sıklıkla kısıtlanmaktadır. Bu çalışma, antiepileptik bir ilaç olan levetirasetamın (LEV) DOX'un indüklediği afektif bozukluklara karşı nöroprotektif etkinliğini araştırmış ve altta yatan nöroenflamatuvar, oksidatif ve nöroendokrin mekanizmaları incelemiştir. Erkek BALB/c fareleri rastgele Kontrol, DOX, DOX+LEV ve LEV gruplarına ayrılmıştır. Nörotoksisiteyi indüklemek amacıyla tek doz intraperitoneal DOX (25 mg/kg) enjeksiyonu kullanılmış olup, LEV (100 mg/kg/gün) ardışık beş gün boyunca uygulanmıştır. Afektif davranışlar, açık alan (OF) ve zorlu yüzme (FST) testleri kullanılarak değerlendirilmiştir. Hipokampal tümör nekrozis faktör-alfa (TNF-α) ve glutatyon (GSH) konsantrasyonlarının yanı sıra serum adrenokortikotropik hormon (ACTH) ve kortizol seviyeleri biyokimyasal olarak ölçülmüştür. DOX maruziyeti; lokomotor bozukluktan bağımsız olarak, OF'de merkez keşfinde anlamlı bir azalma ve FST'de hareketsizlik süresinde artış ile kanıtlandığı üzere, şiddetli anksiyojenik ve depresyon benzeri fenotipleri tetiklemiştir. Söz konusu davranışsal defisitler; belirgin hipokampal GSH tükenmesi, artmış santral TNF-α seviyeleri ve sistemik hipotalamus-hipofiz-adrenal (HPA) ekseni hiperaktivasyonu ile mekanistik olarak bağlantılı bulunmuştur. Kritik bir bulgu olarak, eş zamanlı LEV uygulaması DOX'un indüklediği davranışsal disfonksiyonları tamamen ortadan kaldırmıştır. Bu psikotropik etkinlik; hipokampal oksidatif-enflamatuvar homeostazın yeniden sağlanması ve sistemik ACTH ile kortizol düzeylerinin kesin bir şekilde normalleşmesiyle doğrudan paralellik göstermiştir. Sonuç olarak DOX; nöroenflamasyon, oksidatif stres ve nöroendokrin disregülasyondan oluşan patolojik bir triad tarafından yönlendirilen afektif bozuklukları tetiklemektedir. LEV, bu kaskadları etkili bir şekilde baskılayarak, kemoterapinin indüklediği nöropsikiyatrik komplikasyonları hafifletmeye yönelik adjuvan bir tedavi olarak taşıdığı güçlü translasyonel potansiyeli vurgulamaktadır.

Anahtar Kelimeler

• Afektif bozukluklar
• Hipotalamus-hipofiz-adrenal ekseni
• Doksorubisin
• Levetirasetam
• Nöroenflamasyon

Kaynakça

1. Abd El-Aal, S. A., AbdElrahman, M., Reda, A. M., Afify, H., Ragab, G. M., El-Gazar, A. A., & Ibrahim, S. S. A. (2022). Galangin mitigates DOX-induced cognitive impairment in rats: Implication of NOX-1/Nrf-2/HMGB1/TLR4 and TNF-α/MAPKs/RIPK/MLKL/BDNF. Neurotoxicology, 92, 77–90. https://doi.org/10.1016/j.neuro.2022.07.005
2. Abdelhafez, G. F., Boshra, S. A., Abo-Zalam, H. B., & Radwan, S. M. (2025). Dapagliflozin ameliorates doxorubicin-ınduced chemobrain and cognitive abnormalities in rats: modulation of AKT/GSK-3β and Wnt/β-Catenin pathways. Neurochemical Research, 50(5), 286. https://doi.org/10.1007/s11064-025-04538-0
3. Aboul-Fotouh, S., Elnahas, E. M., Alafifi, A. A., Ahmed, M. Y., & Taha, A. M. (2026). Lithium, a GSK-3β inhibitor, attenuates depression and chemobrain induced by doxorubicin in rats: Emphasis on brain BDNF/TrkB/Akt/GSK-3β/mTOR/Nrf2/HO-1 axis. The Journal of Pharmacology and Experimental Therapeutics, 393(2), 103797. https://doi.org/10.1016/j.jpet.2025.103797
4. Alavi, M. S., Fanoudi, S., Hosseini, M., & Sadeghnia, H. R. (2022). Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer’s disease. Metabolic Brain Disease, 37(3), 689–700. https://doi.org/10.1007/s11011-021-00888-0
5. Aldubayan, M. A., Alsharidah, A. S., Alenezi, S. K., & Alhowail, A. H. (2024). Galantamine mitigates neurotoxicity caused by doxorubicin via reduced neuroinflammation, oxidative stress, and apoptosis in rat model. European Review for Medical and Pharmacological Sciences, 28(2), 805–813. https://doi.org/10.26355/eurrev_202401_35081
6. Alhowail, A. H., & Aldubayan, M. A. (2023). Doxorubicin impairs cognitive function by upregulating AMPAR and NMDAR subunit expression and increasing neuroinflammation, oxidative stress, and apoptosis in the brain. Frontiers in Pharmacology, 14, 1251917. https://doi.org/10.3389/fphar.2023.1251917
7. Alhowail, A., & Almogbel, Y. (2019). Metformin administration increases the survival rate of doxorubicin-treated mice. Die Pharmazie, 74(12), 737–739. https://doi.org/10.1691/ph.2019.9777
8. Aslanlar, D. A., Vişneci, E. F., Oz, M., & Nurullahoglu Atalik, K. E. (2024). N-acetylcysteine ameliorates chemotherapy-induced impaired anxiety and depression-like behaviors by regulating inflammation, oxidative and cholinergic status, and BDNF release. Behavioural Brain Research, 458, 114740. https://doi.org/10.1016/j.bbr.2023.114740

9. Bhutani, V., Varzideh, F., Wilson, S., Kansakar, U., Jankauskas, S. S., & Santulli, G. (2025). Doxorubicin-induced cardiotoxicity: A comprehensive update. Journal of Cardiovascular Development and Disease, 12(6), 207. https://doi.org/10.3390/jcdd12060207
10. Blaser, H., Dostert, C., Mak, T. W., & Brenner, D. (2016). TNF and ROS crosstalk in inflammation. Trends in Cell Biology, 26(4), 249–261. https://doi.org/10.1016/j.tcb.2015.12.002
11. Browning, M., Shear, D. A., Bramlett, H. M., Dixon, C. E., Mondello, S., Schmid, K. E., Poloyac, S. M., Dietrich, W. D., Hayes, R. L., Wang, K. K. W., Povlishock, J. T., Tortella, F. C., & Kochanek, P. M. (2016). Levetiracetam treatment in traumatic brain injury: Operation brain trauma therapy. Journal of Neurotrauma, 33(6), 581–594. https://doi.org/10.1089/neu.2015.4131
12. Cavichioli, A. M., Santos-Silva, T., Grace, A. A., Guimarães, F. S., & Gomes, F. V. (2023). Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats. Schizophrenia Bulletin, 49(1), 68–77. https://doi.org/10.1093/schbul/sbac106
13. Celdran de Castro, A., Nascimento, F. A., Beltran-Corbellini, Á., Toledano, R., Garcia-Morales, I., Gil-Nagel, A., & Aledo-Serrano, Á. (2023). Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion. Seizure, 107, 121–131. https://doi.org/10.1016/j.seizure.2023.03.017
14. Dias-Carvalho, A., Ferreira, M., Reis-Mendes, A., Ferreira, R., de Lourdes Bastos, M., Fernandes, E., Sá, S. I., Capela, J. P., Carvalho, F., & Costa, V. M. (2024). Doxorubicin-induced neurotoxicity differently affects the hippocampal formation subregions in adult mice. Heliyon, 10(11), e31608. https://doi.org/10.1016/j.heliyon.2024.e31608
15. Ebrahim, N. A., Elnagar, M. R., El-Gamal, R., Habotta, O. A., Albadawi, E. A., Albadrani, M., Bahashwan, A. S., & Hassan, H. M. (2024). Melatonin mitigates doxorubicin induced chemo brain in a rat model in a NRF2/p53-SIRT1 dependent pathway. Heliyon, 10(19), e38081. https://doi.org/10.1016/j.heliyon.2024.e38081
16. Eldmnawy, A. T., Tolba, M. F., Elghazaly, H., & Wahdan, S. A. (2025). Trimetazidine protects against doxorubicin-induced chemobrain in rats: Insights into energy imbalance and neuroinflammation. European Journal of Pharmacology, 1008, 178339. https://doi.org/10.1016/j.ejphar.2025.178339
17. González-Fraguela, M. E., Blanco, L., Fernández, C. I., Lorigados, L., Serrano, T., & Fernández, J. L. (2018). Glutathione depletion: Starting point of brain metabolic stress, neuroinflammation and cognitive impairment in rats. Brain Research Bulletin, 137, 120–131. https://doi.org/10.1016/j.brainresbull.2017.11.015
18. Ignacio-Mejía, I., Contreras-García, I. J., Mendoza-Torreblanca, J. G., Medina-Campos, O. N., Pedraza-Chaverri, J., García-Cruz, M. E., Romo-Mancillas, A., Gómez-Manzo, S., Bandala, C., Sánchez-Mendoza, M. E., Pichardo-Macías, L. A., & Cárdenas-Rodríguez, N. (2023). Evaluation of the antioxidant activity of levetiracetam in a temporal lobe epilepsy model. Biomedicines, 11(3), 848. https://doi.org/10.3390/biomedicines11030848
19. Inaba, T., Miyamoto, N., Hira, K., Ueno, Y., Yamashiro, K., Watanabe, M., Shimada, Y., Hattori, N., & Urabe, T. (2019). Protective role of levetiracetam against cognitive impairment and brain white matter damage in mouse prolonged cerebral hypoperfusion. Neuroscience, 414, 255–264. https://doi.org/10.1016/j.neuroscience.2019.07.015
20. Jiang, S. Z., & Eiden, L. E. (2016). Activation of the HPA axis and depression of feeding behavior induced by restraint stress are separately regulated by PACAPergic neurotransmission in the mouse. Stress, 19(4), 374–382. https://doi.org/10.1080/10253890.2016.1174851
21. Kamińska, K., & Cudnoch-Jędrzejewska, A. (2023). A review on the neurotoxic effects of doxorubicin. Neurotoxicity Research, 41(5), 383–397. https://doi.org/10.1007/s12640-023-00652-5
22. Karthikeyan, M. C., Srinivasan, C., Prabhakar, K., Manogar, P., Jayaprakash, A., & Arockiam, A. J. V. (2024). Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells. Medical Oncology, 41(9), 220. https://doi.org/10.1007/s12032-024-02468-5
23. Komoltsev, I. G., & Gulyaeva, N. V. (2022). Brain Trauma, Glucocorticoids and neuroinflammation: Dangerous liaisons for the hippocampus. Biomedicines, 10(5), 1139. https://doi.org/10.3390/biomedicines10051139
24. Manchon, J. F., Dabaghian, Y., Uzor, N. E., Kesler, S. R., Wefel, J. S., & Tsvetkov, A. S. (2016). Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Scientific Reports, 6, 25705. https://doi.org/10.1038/srep25705
25. Mani, V., & Rashed Almutairi, S. (2023). Impact of levetiracetam on cognitive impairment, neuroinflammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats. Saudi Pharmaceutical Journal, 31(9), 101728. https://doi.org/10.1016/j.jsps.2023.101728
26. Mani, V., Arfeen, M., Rabbani, S. I., Shariq, A., & Amirthalingam, P. (2022). Levetiracetam ameliorates doxorubicin-induced chemobrain by enhancing cholinergic transmission and reducing neuroinflammation using an experimental rat model and molecular docking study. Molecules, 27(21), 7364. https://doi.org/10.3390/molecules27217364
27. Matsuo, T., Komori, R., Nakatani, M., Ochi, S., Yokota-Nakatsuma, A., Matsumoto, J., Takata, F., Dohgu, S., Ishihara, Y., & Itoh, K. (2022). Levetiracetam suppresses the infiltration of neutrophils and monocytes and downregulates many inflammatory cytokines during epileptogenesis in pilocarpine-ınduced status epilepticus mice. International Journal of Molecular Sciences, 23(14), 7671. https://doi.org/10.3390/ijms23147671
28. Nandini, H. S., Krishna, K. L., & Apattira, C. (2022). Combination of Ocimum sanctum extract and levetiracetam ameliorates cognitive dysfunction and hippocampal architecture in rat model of Alzheimer’s disease. Journal of Chemical Neuroanatomy, 120, 102069. https://doi.org/10.1016/j.jchemneu.2021.102069
29. Öz, M., & Erdal, H. (2024). A TNF-α inhibitor abolishes sepsis-induced cognitive impairment in mice by modulating acetylcholine and nitric oxide homeostasis, BDNF release, and neuroinflammation. Behavioural Brain Research, 466, 114995. https://doi.org/10.1016/j.bbr.2024.114995
30. Packard, A. E. B., Egan, A. E., & Ulrich-Lai, Y. M. (2016). HPA axis interactions with behavioral systems. Comprehensive Physiology, 6(4), 1897–1934. https://doi.org/10.1002/cphy.c150042
31. Park, K. M., & Bowers, W. J. (2010). Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular Signalling, 22(7), 977–983. https://doi.org/10.1016/j.cellsig.2010.01.010
32. Pickering, M., Cumiskey, D., & O’Connor, J. J. (2005). Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Experimental Physiology, 90(5), 663–670. https://doi.org/10.1113/expphysiol.2005.030734
33. Pribiag, H., & Stellwagen, D. (2013). TNF-α downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABA(A) receptors. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 33(40), 15879–15893. https://doi.org/10.1523/JNEUROSCI.0530-13.2013
34. Savran, M., Asci, S., Gulle, K., Aslankoc, R., Asci, H., Karakuyu, N. F., Erzurumlu, Y., & Kaynak, M. (2024). Agomelatine ameliorates doxorubicin-induced cortical and hippocampal brain injury via inhibition of TNF-alpha/NF-kB pathway. Toxicology Mechanisms and Methods, 34(4), 359–368. https://doi.org/10.1080/15376516.2023.2291123
35. Shaker, F. H., El-Derany, M. O., Wahdan, S. A., El-Demerdash, E., & El-Mesallamy, H. O. (2021). Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats. Life Sciences, 269, 119078. https://doi.org/10.1016/j.lfs.2021.119078
36. Sun, D., Coleclough, C., Cao, L., Hu, X., Sun, S., & Whitaker, J. N. (1998). Reciprocal stimulation between TNF-alpha and nitric oxide may exacerbate CNS inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 89(1–2), 122–130. https://doi.org/10.1016/s0165-5728(98)00124-6
37. Thomas, T. C., Beitchman, J. A., Pomerleau, F., Noel, T., Jungsuwadee, P., Butterfield, D. A., Clair, D. K. S., Vore, M., & Gerhardt, G. A. (2017). Acute treatment with doxorubicin affects glutamate neurotransmission in the mouse frontal cortex and hippocampus. Brain Research, 1672, 10–17. https://doi.org/10.1016/j.brainres.2017.07.003
38. Ueda, Y., Doi, T., Takaki, M., Nagatomo, K., Nakajima, A., & Willmore, L. J. (2009). Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: In vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Research, 1266, 1–7. https://doi.org/10.1016/j.brainres.2009.02.040
39. Wang, G., Cao, L., Li, S., Zhang, M., Li, Y., Duan, J., Li, Y., Hu, Z., Wu, J., Li, T., Jiang, M., & Lu, J. (2024). Corticosterone impairs hippocampal neurogenesis and behaviors through p21-mediated ROS accumulation. Biomolecules, 14(3), 268. https://doi.org/10.3390/biom14030268
40. Wang, M.J., Jiang, L., Chen, H.S., & Cheng, L. (2019). Levetiracetam protects against cognitive ımpairment of subthreshold convulsant discharge model rats by activating protein kinase c (PKC)-growth-associated protein 43 (GAP-43)-calmodulin-dependent protein kinase (CaMK) signal transduction pathway. Medical Science Monitor, 25, 4627–4638. https://doi.org/10.12659/MSM.913542
41. Wei, T., Wang, L., Tang, J., Ashaolu, T. J., & Olatunji, O. J. (2022). Protective effect of Juglanin against doxorubicin-induced cognitive impairment in rats: Effect on oxidative, inflammatory and apoptotic machineries. Metabolic Brain Disease, 37(4), 1185–1195. https://doi.org/10.1007/s11011-022-00923-8
42. Yeni, Y., Cicek, B., Hacimuftuoglu, A., Ozkaraca, M., & Lacin, B. B. (2025). Protective effect of HMG-CoA reductase ınhibitor rosuvastatin on doxorubicin-ınduced cognitive ımpairment, oxidative stress and neuroinflammation: possible role of CREB, ERK1/2, and BDNF. Journal of Neuroimmune Pharmacology, 20(1), 53. https://doi.org/10.1007/s11481-025-10213-6